RxDoctor Payments Data

Kathleen Tong, MD

Internal Medicine · San Francisco, CANPI 1225013923

Payments from drug & device makers

$202,007in general payments, 2019–2025

Across 283 payments — averaging $713.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$110K
  • Abbott$48K
  • Boehringer Ingelheim$15K
  • Novartis$10K
  • Actelion Pharmaceuticals US, Inc.$6K
  • Lilly USA, LLC$5K
  • plus $7K from 23 others

What the payments were for

  • Consulting fees$5,73011%
  • Speaking & faculty fees$25,60548%
  • Travel & lodging$5,58610%
  • Food & beverage$16,68931%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$202,007 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$63,286
Medicare patients
362
Services billed
765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan26$310,794
EliquisApixaban104$102,613
JardianceEmpagliflozin53$49,186
EntrestoSacubitril/Valsartan36$38,913
Praluent PenAlirocumab18$15,528
Sildenafil Citrate23$5,429
Metoprolol Succinate118$1,503
Potassium Chloride72$1,197
Telmisartan11$1,174
Torsemide32$995
Midodrine Hcl11$935
Atorvastatin Calcium77$657
Amiodarone Hcl46$588
Amlodipine Besylate68$547
ClopidogrelClopidogrel Bisulfate43$391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$5,999$310,79426 claims
Boehringer IngelheimJardiance$15,426$49,18653 claims
NovartisEntresto$10,217$38,91336 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →